Pharming Group (PHAR)
(Delayed Data from NSDQ)
$10.96 USD
-0.15 (-1.35%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.08 +0.12 (1.09%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Pharming Group N.V. Sponsored ADR's return on equity, or ROE, is -3.38% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that PHAR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
PHAR 10.96 -0.15(-1.35%)
Will PHAR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAR
New Strong Buy Stocks for August 1st
Best Momentum Stocks to Buy for July 25th
PHAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 25th
Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
Other News for PHAR
Pharming (PHAR) Stock Target Raised by Oppenheimer Following Q2 Results
Pharming price target raised by $1 at Oppenheimer, here's why
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation
Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M